Basics Myriad Genetics, Inc. Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs. IPO Date: October 6, 1995 Sector: Healthcare Industry: Biotech Market Cap: $615.02M Activated in VL: True Average Daily Range Avg Daily Range: $0.50 | 1.90% Avg Daily Range (30 D): $0.17 | 3.21% Avg Daily Range (90 D): $0.18 | 3.58% Institutional Daily Volume Avg Daily Volume: .84M Avg Daily Volume (30 D): 1.77M Avg Daily Volume (90 D): 1.8M Trade Size Avg Trade Size (Sh.): 122 Avg Trade Size (Sh.) (30 D): 105 Avg Trade Size (Sh.) (90 D): 108 Institutional Trades Total Inst.Trades: 11,644 Avg Inst. Trade: $1.85M Avg Inst. Trade (30 D): $1.19M Avg Inst. Trade (90 D): $1.55M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.5M Avg Closing Trade (30 D): $1.04M Avg Closing Trade (90 D): $1.54M Avg Closing Volume: 106.75K     News Sep 4, 2025 @ 11:00 PM Myriad Genetics Announces Precise MRD Clinical Dat... Source: Myriad Genetics Aug 28, 2025 @ 3:00 PM Genetic Material Market Size, Trends and Top Compa... Source: Towards Healthcare Aug 22, 2025 @ 1:00 PM Global Liquid Biopsy Market Set to Reach USD 7.05 ... Source: Marketsandmarkets Aug 13, 2025 @ 12:00 PM New Myriad Genetics Survey Uncovers Women Fear Scr... Source: Myriad Genetics May 8, 2025 @ 9:28 PM Securities Fraud Investigation Into Myriad Genetic... Source: Business Wire Financials   TTM Q2 2025 Q1 2025 Basic EPS $-4.3 $-3.57 $ Diluted EPS $-4.3 $-3.57 $ Revenue $ 832.9M $ 213.1M $ 195.9M Gross Profit $ 586.7M $ 151.8M $ 134.2M Net Income / Loss $ -395.2M $ -330.5M $ -.1M Operating Income / Loss $ -417.2M $ -329.2M $ -29M Cost of Revenue $ 246.2M $ 61.3M $ 61.7M Net Cash Flow $ -19.8M $ -17.3M $ -10.9M PE Ratio     Splits Mar 26, 2009:   2:1 Sep 12, 2000:   2:1